Compound ID | 1439
Class: Bacterial topoisomerase inhibitor
Spectrum of activity: | Gram-positive |
Details of activity: | Effective against S.aureus and S. pneumoniae. Discontinued |
Institute where first reported: | AstraZeneca, UK |
Year first mentioned: | 2009 |
Highest developmental phase: | Phase 1 |
Development status: | Inactive |
Chemical structure(s): | |||||||||||
|
|
External links: | |
PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/25008769 |
Citations: |
|